Matthew Taylor

Assistant Professor

  • 3643 Citations
  • 13 h-Index
20102019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Matthew Taylor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Neoplasms Medicine & Life Sciences
Thyroid Neoplasms Medicine & Life Sciences
Safety Medicine & Life Sciences
Melanoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Local Neoplasm Recurrences Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2010 2019

  • 3643 Citations
  • 13 h-Index
  • 25 Article
  • 1 Comment/debate
5 Citations (Scopus)

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial

Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 12.

Research output: Contribution to journalArticle

Melanoma
Neoplasms
Therapeutics
Disease-Free Survival
Survival

Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)

Berry, S., Giraldo, N., Nguyen, P., Green, B., Xu, H., Ogurtsova, A., Soni, A., Succaria, F., Wang, D., Roberts, C., Stein, J., Engle, E., Pardoll, D., Anders, R., Cottrell, T., Taube, J. M., Tran, B., Voskoboynik, M., Kuo, J., Bang, Y. L. & 72 others, Chung, H. C., Ahn, M. J., Kim, S. W., Perera, A., Freeman, D., Achour, I., Faggioni, R., Xiao, F., Ferte, C., Lemech, C., Meric-Bernstam, F., Werner, T., Hodi, S., Messersmith, W., Lewis, N., Talluto, C., Dostalek, M., Tao, A., McWhirter, S., Trujillo, D., Luke, J., Xu, C., Bomarelli, B., Qi, J., Qin, G., Yu, H., Jenkins, M., Lo, K. M., Halle, J. P., Lan, Y., Taylor, M., Vogelzang, N., Cohn, A., Stepan, D., Shumaker, R., Dutcus, C., Guo, M., Schmidt, E., Rasco, D., Brose, M., Di Simone, C., Jain, S., Richards, D., Encarnacion, C., Vogelzeng, N., Mier, J., An, J., Yang, Y. Y., Lee, W. H., Yang, J., Kim, J. K., Kim, H. G., Paek, S. H., Lee, J. W., Woo, J., Kim, J. B., Kwon, H., Lim, W., Paik, N. S., Kim, Y. K., Moon, B. I., Janku, F., Tan, D., Martin-Liberal, J., Takahashi, S., Geva, R., Gucalp, A., Chen, X., Subramanian, K., Mataraza, J., Wheler, J. & Bedard, P., Feb 13 2019, In : Journal for immunotherapy of cancer. 7, 1, 46.

Research output: Contribution to journalArticle

Open Access
Immunotherapy
Publications
Neoplasms
13 Citations (Scopus)

Efficacy and Safety of Avelumab for Patients with Recurrent or Refractory Ovarian Cancer: Phase 1b Results from the JAVELIN Solid Tumor Trial

Disis, M. L., Taylor, M., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., Hamilton, E. P., Annunziata, C. M., Grote, H. J., Von Heydebreck, A., Grewal, J., Chand, V. & Gulley, J. L., Jan 1 2019, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

Patient Safety
Ovarian Neoplasms
Neoplasms
avelumab
Platinum
10 Citations (Scopus)

Larotrectinib in adult patients with solid tumours: A multi-centre, open-label, phase i dose-escalation study

Hong, D. S., Bauer, T. M., Lee, J. J., Dowlati, A., Brose, M. S., Farago, A. F., Taylor, M., Shaw, A. T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B. B., Ebata, K., Cruickshank, S., Cox, M. C., Burris, H. A. & Doebele, R. C., Feb 1 2019, In : Annals of Oncology. 30, 2, p. 325-331 7 p.

Research output: Contribution to journalArticle

Open Access
Gene Fusion
Neoplasms
Maximum Tolerated Dose
Anemia
Appointments and Schedules
16 Citations (Scopus)

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., Schmidt, E. V., Guo, M., Sachdev, P., Shumaker, R., Aghajanian, C. & Taylor, M., May 1 2019, In : The Lancet Oncology. 20, 5, p. 711-718 8 p.

Research output: Contribution to journalArticle

Endometrial Neoplasms
Therapeutics
Hypothyroidism
Diarrhea
pembrolizumab